ArticleDrug design, development and therapy2024
Alkannin Induces G2/M-Phase Arrest, Apoptosis, and Inhibition of Invasion by Targeting GSK3β in Esophageal Squamous Cell Carcinoma.
Article in Drug design, development and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Interaction of Alkannin with CPEB4 Contributes to Its Antitumor Effects in Melanoma.Biomolecules · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Esophageal squamous cell carcinoma (ESCC) is the most common malignant tumor of the upper gastrointestinal tract, characterized by high mortality and poor prognosis. There is an urgent need for the development of more effective drugs. Alkannin has been shown to inhibit the progression of various cancers, but its inhibitory effects on ESCC remain unclear. This study aims to investigate the therapeutic effects of Alkannin on ESCC and elucidate its potential targets and molecular mechanisms. Methods: Cell Counting Kit-8 (CCK-8) assays, colony formation assays, Hoechst 33342 staining, wound healing assays, Transwell migration assays, flow cytometry, and Western blotting were used to investigate the therapeutic effects of Alkannin on ESCC in vitro. Transcriptome sequencing and network pharmacology were employed to analyze the potential targets and pathways affected by Alkannin treatment. The anticancer effects of Alkannin in vivo were assessed in a nude mouse model. Results: Alkannin suppressed cell proliferation, invasion, migration, and induced ESCC cell apoptosis. Mechanistic studies indicated that Alkannin inhibits ESCC by inducing G2/M-phase cell cycle arrest by targeting Glycogen Synthase Kinase 3β (GSK3β). Consistently, in vivo administration of Alkannin significantly reduced the growth of ESCC tumors in nude mice. Conclusion: This study is the first to demonstrate that Alkannin, by targeting GSK3β, induces G2/M-phase arrest in ESCC cells, thereby inhibiting migration, invasion, and inducing apoptosis, suggesting that Alkannin may be a promising antitumor agent for treating ESCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.